Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the
advent of effective inhibitors of B-cell receptor signaling such as ibrutinib–a first-in-class …

Bruton´ s tyrosine kinase (BTK) inhibitor (BTKi) s block the B-cell receptor (BCR) signaling
cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant …

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed
considerably with the introduction of very effective oral targeted therapies (such as ibrutinib …

Cancer is a disease involving the abnormal accumulation of cells resulting from an
imbalance of proliferation and programmed cell death. This review focuses on the …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

Bromodomain and extra-terminal (BET) family proteins are key regulators of gene
expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved …

Neuronal cell death is often triggered by events that involve intracellular increases in Ca 2+.
Under resting conditions, the intracellular Ca 2+ concentration is tightly controlled by a …

Background Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the
B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in …

High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic
resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the …

The intracellular protein B‐cell‐lymphoma‐2 (BCL2) has been considered an attractive
target for cancer therapy since the discovery of its function as a major promoter of cell …